More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...
About 140 million Americans, more than half of the nation's adults, could be considered candidates for weight loss drugs ...
There's been pressure put on Novo Nordisk to lower the cost of Ozempic and Wegovy. In late September, company CEO Lars ...
More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.